Hemophilia B – Executive Insights – Hemophilia B | Executive Insights (US)
Hemophilia B is a genetic disorder caused by a deficiency in clotting factor IX. Current treatment is dominated by factor IX replacement therapies (in non-inhibitor patients) and bypass agents (in inhibitor patients). The main goal of factor IX prophylaxis and bypass agent treatment is to improve patients’ quality of life by reducing the frequency and severity of bleeding episodes. The hemophilia B therapy market is expected to transform over the next 10 years owing to the entry of several nonfactor and gene therapies. Supported by insights garnered from thought-leader interviews conducted by Clarivate, we analyze the current and future treatment of hemophilia B and the competitive landscape and identify key unmet needs and market drivers and challenges.
Questions answered
- What is the prevalence of hemophilia B in the United States? What are the key patient segments?
- What is the treatment algorithm for hemophilia B (+/- inhibitors)?
- Which drugs / drug classes are currently used in the management of hemophilia B? What are their key advantages and disadvantages?
- How will the use of standard half-life (SHL) and extended half-life (EHL) factor IX concentrate evolve with the launch of nonfactor therapies?
- What clinical roles will the emerging therapies fitusiran, concizumab, marstacimab, and gene therapy play in the treatment of hemophilia B?
- Which companies are currently offering or developing drugs to treat hemophilia B? What is their current and future market influence?
- What are the key unmet needs in hemophilia B treatment? How can they be addressed by pipeline drug therapies?
- What are the opinions of KOLs on different aspects of hemophilia B?
Product description
Executive Insights provides indication-specific market intelligence withworld-class epidemiology and keen insight into current treatment paradigms, biotherapeutic pipelines, key clinical unmet needs, and competitive landscapes, supported by primary and secondary research. This solution provides succinct insights to any biopharma function or business professional looking to quickly grasp a new indication of interest.
Geography: United States
Primary research: Three KOL interviews from February 2023
Key companies covered: Centessa Pharmaceuticals, CSL Behring, Freeline Therapeutics, Grifols, HEMA Biologics, Medexus Pharmaceuticals, Novo Nordisk, Pfizer, Sanofi, Takeda
Key drugs covered: AlphaNine, Alprolix, BeneFIX, concizumab, FEIBA, fidanacogene elaparvovec, fitusiran, Hemgenix, Idelvion, IXinity, marstacimab, NovoSeven, Profilnine, Rebinyn, Rixubis, SerpinPC, Sevenfact, verbrinacogene setparvovec
Yogesh Shelke, M.B.A. (Pharm.), Manager, Cardiovascular, Metabolic, Renal, and Hematology. Before joining Clarivate, he was instrumental in providing actionable insights to clients from various leading pharmaceutical companies regarding competitive intelligence, market sizing and forecasting, pipeline analysis, situational analysis, unmet need analysis, and market entry strategies in a variety of therapeutic areas. He holds a bachelor’s degree in pharmacy from Pune University and a master’s degree in pharmaceutical marketing from the National Institute of Pharmaceutical Education and Research in Mohali, India.
Graeme Green, M.Sc., Ph.D., is the head of the Cardiovascular, Metabolic, Renal, and Hematology (CMRH) group at Clarivate, where he leads a team of analysts investigating indications ranging from type 2 diabetes to chronic heart failure. With more than 14 years of market experience in this space, he has managed and authored a vast array of content. Using various forecasting and assessment methodologies, he has written indication-specific insight reports and provided analysis on market dynamics, drug development, and corporate strategy. Prior to moving to the pharmaceutical sector, he worked for a financial management consultancy. Dr. Green holds a Ph.D. in molecular medical microbiology and an M.Sc. in forensic science from King’s College London.